학술논문
European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene
Document Type
Article
Author
Source
In Neuromuscular Disorders January 2015 25(1):5-13
Subject
Language
ISSN
0960-8966